{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123281","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.868696+00:00","generated_at":"2026-05-30T03:47:32.707224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026","bullets":["Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.","Cash and equivalents $56.5M at Sept 30, 2024, down from $111.5M at Dec 31, 2023.","Ozuriftamab vedotin (CAB-ROR2-ADC) shows median OS ~9 months in heavily pretreated SCCHN; FDA supported pivotal trial design.","Evalstotug (CAB-CTLA-4) + PD-1 produced tumor reduction in all 8 first-line melanoma patients, with 1 CR and 3 PRs.","Worldwide license agreement for CAB-Nectin-4 TCE with Context Therapeutics for up to $133.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123281","json":"https://secwatch.observer/filing/0000950170-24-123281.json","markdown":"https://secwatch.observer/filing/0000950170-24-123281.md","text":"https://secwatch.observer/filing/0000950170-24-123281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/0000950170-24-123281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/bcab-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:47:32.707224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}